ScholarIQanswers from OpenAlex & ORCID
B Charbonnel
ResearcherPublications, citations & collaboration network
B Charbonnel is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does B Charbonnel have?
ScholarIQindexed works
B Charbonnel has 421 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does B Charbonnel have?
ScholarIQcitation count
B Charbonnel has 19,917 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of B Charbonnel?
ScholarIQh-index
B Charbonnel has an h-index of 56 in OpenAlex.
What is the i10-index of B Charbonnel?
ScholarIQi10-index
B Charbonnel has an i10-index of 135 in OpenAlex.
What is the ORCID of B Charbonnel?
ScholarIQorcid
The ORCID for B Charbonnel is on the source record.
What is the OpenAlex record for B Charbonnel?
ScholarIQopenalex
The OpenAlex for B Charbonnel is on the source record.
What are the most-cited papers on B Charbonnel?
ScholarIQmost cited works
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
John Dormandy, B Charbonnel, D.J.A. Eckland, Erland Erdmann, Massimo Massi‐Benedetti, Ian K. Moules, Allan M. Skene, Meng H. Tan, Pierre J. Lefèbvre, Gordon Murray, Eberhard Standl, Robert G. Wilcox, Lars Wilhelmsen, John Betteridge, Kåre I. Birkeland, Alain Golay, Robert J. Heine, László Korányi, Markku Laakso, Marian Mokáň, Antanas Norkus, Valdis Pīrāgs, Toomas Podar, André Scheen, Werner A. Scherbaum, Guntram Schernthaner, Ole Schmitz, J Skrha, Ulf Smith, J Tatoń
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors Task Force Members, L Rydén, Eberhard Standl, M. Bartnik, Greet Van den Berghe, John Betteridge, Menko‐Jan de Boer, Francesco Cosentino, Bengt Jönsson, Markku Laakso, K. Malmberg, Silvia G. Priori, Jan Östergren, J Tuomilehto, Inga S. Þráinsdóttir, Other Contributors, Ilse Vanhorebeek, Marco Stramba‐Badiale, Peter Lindgren, Qing Qiao, Silvia G. Priori, J J Blanc, Andrzej Budaj, A. John Camm, V. Dean, Jaap W. Deckers, Kenneth Dickstein, J. Lekakis, Keith McGregor, Marco Metra, João Morais, A. Osterspey, Juan Tamargo, José Luís Zamorano, Document Reviewers, Jaap W. Deckers, M Bertrand, B Charbonnel, Erland Erdmann, Ele Ferrannini, Allan Flyvbjerg, H. Gohlke, J.R.G. Juanatey, Ian Graham, Pedro Monteiro, Klaus G. Parhofer, Kalevi Pyörälà, Itamar Raz, Guntram Schernthaner, Massimo Volpe, David M. Wood
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon, Richard E. Pratley, Samuel Dagogo‐Jack, James P. Mancuso, Susan Huyck, Urszula Masiukiewicz, B Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino, Weichung Shih, Ira Gantz, Steven G. Terra, David Z.I. Cherney, Darren K. McGuire
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
Darren K. McGuire, Weichung Shih, Francesco Cosentino, B Charbonnel, David Z.I. Cherney, Samuel Dagogo‐Jack, Richard E. Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck, Ira Gantz, Steven G. Terra, Urszula Masiukiewicz, Christopher P. Cannon